Table 2.
Multivariate analysis in 494 patients with metastatic nodes
| Variables | OS | DFS | DFFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Gender | 0.158 | 0.662 | 0.708 | |||
| Male | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Female | 1.47 (0.86–2.52) | 1.10 (0.72–1.66) | 0.91 (0.55–1.50) | |||
| Age | 0.089 | 0.018 | 0.049 | |||
| ≤ 47 years | 1 (reference) | 1 (reference) | 1 (reference) | |||
| > 47 years | 1.56 (0.93–2.60) | 1.56 (1.08–2.26) | 1.53 (1.00–2.33) | |||
| T stage | < 0.001 | 0.011 | 0.067 | |||
| T1 | 1 (reference) | 1 (reference) | 1 (reference) | |||
| T2 | 4.42 (0.57–34.38) | 0.156 | 2.67 (0.93–7.68) | 0.069 | 2.10 (0.71–6.18) | 0.178 |
| T3 | 4.61 (0.62–34.46) | 0.137 | 2.74 (0.98–7.66) | 0.055 | 2.20 (0.78–6.23) | 0.139 |
| T4 | 19.72 (2.64–147.48) | 0.004 | 4.71 (1.63–13.61) | 0.004 | 3.60 (1.22–10.63) | 0.021 |
| Chemotherapy | 0.051 | 0.799 | 0.924 | |||
| CCRT alone | 1 (reference) | 1 (reference) | 1 (reference) | |||
| CCRT + NAC/AC | 0.47 (0.22–1.00) | 0.92 (0.47–1.79) | 0.96 (0.43–2.14) | |||
| Laterality of cervical positive LNs | 0.050 | 0.185 | 0.050 | |||
| RLNs only | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Unilateral | 0.47 (0.13–1.72) | 0.252 | 0.74 (0.26–2.06) | 0.559 | 0.41 (0.12–1.40) | 0.155 |
| Bilateral | 1.02 (0.29–3.55) | 0.974 | 1.08 (0.39–2.98) | 0.882 | 0.72 (0.22–2.41) | 0.594 |
| Location of positive LNs | 0.007 | 0.008 | 0.012 | |||
| Upper neck only | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Upper + lower neck | 2.21 (1.24–3.93) | 1.77 (1.16–2.70) | 1.84 (1.14–2.96) | |||
| Size of positive LNs | 0.937 | 0.202 | 0.140 | |||
| ≤ 6 cm | 1 (reference) | 1 (reference) | 1 (reference) | |||
| > 6 cm | 0.97 (0.44–2.12) | 1.39 (0.84–2.30) | 1.50 (0.88–2.58) | |||
| CNN | 0.468 | 0.586 | 0.637 | |||
| No | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Yes | 0.81 (0.45–1.44) | 0.89 (0.59–1.35) | 1.12 (0.70–1.79) | |||
| rENE | 0.043 | 0.053 | 0.045 | |||
| No | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Yes | 2.50 (1.03–6.08) | 2.02 (0.99–4.12) | 2.58 (1.02–6.51) | |||
| Cervical rCAI | 0.313 | 0.010 | 0.045 | |||
| No | 1 (reference) | 1 (reference) | 1 (reference) | |||
| Yes | 1.40 (0.73–2.70) | 1.91 (1.17–3.12) | 1.79 (1.01–3.17) |
Abbreviations: OS overall survival, DFS disease-free survival, DFFS distant failure-free survival, HR hazard ratio, CI confidence interval, CCRT concurrent chemoradiotherapy, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, LN lymph node, RLN retropharyngeal lymph node, CNN cervical node necrosis, rENE radiological extranodal extension, rCAI radiological carotid artery invasion